JPMorgan raised the firm’s price target on Argenx (ARGX) to $1,100 from $925 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $1,110 from $1,070 at Morgan Stanley
- Argenx downgraded to Peer Perform from Outperform at Wolfe Research
- argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting
- Argenx price target raised to $1,124 from $1,041 at Citi
- Argenx removed from Best Ideas List at Wedbush